Navigation Links
Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association

-- Median time to pain progression is 66.1 weeks for the satraplatin arm compared with 22.3 weeks for the placebo arm -- Hazard ratio of 0.64 (95% CI: 0.51-0.79, p<0.001), representing a 36% reduction in the relative risk of pain progression

MARTINSRIED/MUNICH, Germany, May 21, 2007 /PRNewswire-FirstCall/ -- PRINCETON, N.J., and BOULDER, Colo. -- GPC Biotech AG and Pharmion Corporation today announced the presentation of additional data from the double-blind, randomized satraplatin Phase 3 registrational trial, the SPARC trial (Satraplatin and Prednisone Against Refractory Cancer). The data are being presented today at the Annual Meeting of the American Urological Association (AUA) in Anaheim, California. The SPARC trial is evaluating satraplatin plus prednisone versus placebo plus prednisone in 950 patients with hormone-refractory prostate cancer (HRPC) whose prior chemotherapy has failed. An NDA for satraplatin is currently under priority review by the U.S. FDA.

"Patients with metastatic hormone-refractory prostate cancer frequently suffer from substantial pain associated with bone metastases. Thus, pain control for these patients constitutes a major challenge and is an important goal when caring for them," said Oliver Sartor, M.D., Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Associate Professor at Harvard Medical School, Boston, MA, and principal investigator of the SPARC trial, who is presenting the satraplatin data today. "In addition to the very encouraging results for progression-free survival demonstrating a 33% lower risk of progression compared to control, it is exciting to see that the SPARC trial results show that treatment with satraplatin also results in a statistically significant improvement in time to pain progression."

Data presented today showed that the median time to pain progression was 66.1 weeks for the satraplatin arm compared with 22.3 weeks for
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
3. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
4. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
5. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
6. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
7. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
8. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
11. PTC Therapeutics Announces Additional Positive Interim Phase 2 Results of PTC124 in Duchenne Muscular Dystrophy
Post Your Comments:
(Date:1/23/2015)... Jan. 23, 2015  Pete Rose, baseball,s all-time hits leader, is ... pain reliever Myoflex, Ducere Pharma has announced. "Pete,s ... excited to have him on board with Myoflex," said Ducere ... a legendary player who is known across all generations. The ...
(Date:1/23/2015)... Jan. 23, 2015  iMD Companies, Inc. (ICBU) has repositioned itself ... share and grab a foothold in the hydroponic, hemp and ... and a presence in the sector, and recently partnering with ... of hemp and medical marijuana, iMD is committing to bring ...
(Date:1/23/2015)... 23, 2015   Leatt Corporation  (OTCQB: LEAT), a global ... all forms of sports, including extreme motor sports, and ... today that the UISP Lega Motociclismo Lombardia, an Italian ... to wear a neck brace during its racing competitions.  ...
Breaking Medicine Technology:Pete Rose bets on Myoflex to relieve aches and pains 2iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3
... Expected to be Reported in Q2 2008, ... (Nasdaq: ALXA ) announced today that it ... clinical trial with AZ-002,(Staccato(R) alprazolam) in patients with ... developed for the acute treatment of,panic attacks associated ...
... Quantum Immunologics, Inc. ("QI"),announces the commencement of ... and efficacy of a novel anti-cancer vaccine/immunotherapy that ... breast cancer. Patients accepted,into the study have previously ... radiation and/or chemotherapy. QI has commissioned,the study to ...
Cached Medicine Technology:Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients 2Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients 3Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients 4Quantum Immunologics, Inc. and the South Alabama Medical Science Foundation Announce an Early Clinical Evaluation of a Novel Immuno-therapeutic Vaccine for Treating Advanced Human Breast Carcinomas 2Quantum Immunologics, Inc. and the South Alabama Medical Science Foundation Announce an Early Clinical Evaluation of a Novel Immuno-therapeutic Vaccine for Treating Advanced Human Breast Carcinomas 3
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota (Blue ... means to “Live Fearless.” , The “Faces of ... stories about how they or someone they know has faced ... in the moment. By telling these types of stories through ...
(Date:1/22/2015)... A new white paper by The ... in the long-term care environment as well as provides ... The paper, “The Power of Person-Centeredness in Long-Term Care: ... of the patient, resident and family experience in long-term ...
(Date:1/22/2015)... 22, 2015 Carinsurancesavings.biz has released a new ... and dismemberment insurance . , Purchasing an accidental death ... very advantageous. This type of rider provides benefits if the ... be considered a lesser form of life insurance. , ...
(Date:1/22/2015)... (PRWEB) January 23, 2015 Recently, Weddingshe.com has ... catalog, and has announced its highest annual revenues in the ... on its popular glamorous wedding dresses. , According to the ... important wedding dress promotions for them in 2015. This point ...
(Date:1/22/2015)... IPSWICH, Mass. (PRWEB) January 22, 2015 ... Association (AMA) are expanding their relationship in an effort ... journals around the world. While EBSCO has long made AMA ... as a sales agent for The JAMA Network. ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4
... New England,s largest fertility clinics expands to 12 ... Science Center,(RSC) of New England, the seventh largest ... partnership with Lowell General Hospital with,the opening of ... North Chelmsford at 10 Research Place, Suite 250., ...
... of low-risk patients are almost always benign and do not ... patients. This finding is significant because incidental adrenal lesions ... say. , The study included 973 patients with 1,049 adrenal ... of a hormonally active adrenal mass, said Julie H. Song, ...
... for evaluation of small bowel pathologies (e.g., bleeding sources). ... time and reduced visibility by air and residual material. ... defoaming agents) have been tried to improve the quality ... has been recommended for bowel preparation for CE. , ...
... Na+/H+ exchanger (NHE1) is a transmembrane protein found in ... evacuate excessive H+ in the cytoplasm by means of ... of the upregulation of NHE-1 gene expression in human ... apoptosis of tumor cells, which is helpful for the ...
... Palmetto GBA, a,leading provider of technical and administrative services ... a retired Air Force,colonel and former executive with health ... board of directors., Shields, a resident of Isle ... for Louisville, Ky.-based Humana, where he had served as ...
... interferes with abnormal cell growth seen in pulmonary hypertension ... drug sorafenib (Nexavar) shows promise as a treatment for ... Center study. , During the study, nine patients took ... those given to cancer patients. The patients also continued ...
Cached Medicine News:Health News:Reproductive Science Center and Lowell General Hospital Announce Partnership in Infertility Treatment 2Health News:How does sodium phosphate combined with bisacodyl affect small intestine? 2Health News:Sorafenib Shows Promise for Heart-Lung Disease 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: